PREMATURE OVARIAN FAILURE
##semicolon##
Keywords: premature ovarian failure, ethiology,diagnose and treat.Abstrak
POF is a fairly common problem. The age of cessation of ovarian function and the onset of menopause is influenced by a number of factors that can be divided into two groups: modifiable (medical, social, and environmental factors) and non-modifiable (genetic). Heredity is a powerful predictor of accelerated depletion of the follicular apparatus and the onset of early menopause.
##submission.citations##
1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027
2. Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547
3. Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1
4. van Kasteren Y.M., Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483
5. Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1
6. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046
7. Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110
8. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041
9. Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017
10. Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330
11. Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292
12. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415
13. Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374
14. Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261
15. Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for dia- betes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0
16. Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516
17. Ostberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypo- gonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.x
18. El Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003
19. Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512
20. Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82
21. Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358
22. Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010
